DUBLIN, March 10, 2022–(BUSINESS WIRE)–The “Chinese Liraglutide Market Investigation Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk A/S. Its VICTOZA product was first launched in the EU in July 2009 and was first approved to enter the Chinese market in 2011.
Liraglutide is a drug used for the treatment of type 2 diabetes or obesity. As one of the most important GLP-1 receptor agonists, liraglutide is the only analogue of human GLP-1 shown to reduce the risk of cardiovascular death. In 2020, Novo Nordisk A/S is the only manufacturer in the Chinese liraglutide market.
According to the market research, the sales of Liraglutide increased year by year from 2016 to 2020. Liraglutide was included in the medical insurance reimbursement catalog in 2017. Therefore, the growth in the value of sales in 2018 was the most obvious, rising from CNY 51.98 million in 2017 to CNY 114.39 million in 2018.
The annual growth rate is approximately 120.05%. Due to the impact of the COVID-19 epidemic, the sales value of Liraglutide in China reached CNY 286.73 million in 2020, and the growth rate is 30.43%, which is lower than that of 2019. The CAGR of sales value of Liraglutide from 2016 to 2020 is 61.87% in China.
The analyst expects the sales value of Liraglutide to experience renewed growth from 2021 to 2025 with the effective easing of the COVID-19 outbreak. The patent of Liraglutide has expired and the drug registration application for injection of Liraglutide produced by Shenzhen Hanyu Pharmaceutical Co., Ltd. was officially accepted in 2019.
Since then, the number of manufacturers will gradually increase, the market will continue to expand, and the price will decrease, which will lead to the increase in sales and sales volume of Liraglutide. Moreover, the huge patient population will also enable the Liraglutide market to continue to grow.
In China, there is an average of 1 in 10 adults with diabetes, and type 2 diabetes patients account for more than 90% of all diabetes patients. The large number of patients has also increased the demand for Liraglutide. Therefore, its sales will continue to grow as the market develops in the future.
The impact of COVID-19 on the Chinese liraglutide market
Liraglutide sales value in China 2016-2020
Competitive Landscape of Chinese Liraglutide Market
Liraglutide price in China
Liraglutide Price in China by Regions and Manufacturers
Analysis of factors affecting the development of the Chinese liraglutide market
China Liraglutide Market Outlook from 2021 to 2025
Main topics covered:
1 Relevant concepts of liraglutide
1.1 Indications for liraglutide
1.2 Liraglutide Development in China
1.3 Government approval of liraglutide in China
1.4 The impact of COVID-19 on Liraglutide sales in China
2 China Liraglutide Sales, 2016-2020
2.1 Liraglutide Sales Value
2.1.1 Overall sales value
2.1.2 Sales Value by Region
2.2 Liraglutide Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 China Liraglutide Sales by Dosage Form, 2016-2020
2.3.2 Analysis of other dosage forms
3 Analysis of Liraglutide Key Manufacturers in China, 2016-2020
3.1 Liraglutide Major Manufacturers Market Share Analysis
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 Novo Nordisk A/S
3.2.1 Company profile
3.2.2 VICTOZA (Liraglutide by Novo Nordisk A/S) Sales in China
4 Liraglutide Price for Different Manufacturers in China, 2020-2021
4.1 Novo Nordisk A/S (VICTOZA)
4.2 Analysis of other companies
5 China Liraglutide Drug Market Outlook, 2021-2025
5.1 Influencing Factors of China Liraglutide Market Development
5.1.1 The impact of COVID-19 on the Chinese liraglutide market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
For more information on this report, visit https://www.researchandmarkets.com/r/t743f1
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220310005664/en/
Laura Wood, Senior Press Officer
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900